EI
EWTX icon

EAM Investors’s Edgewise Therapeutics EWTX Stock Holding History

EAM Investors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-91,333
Closed -$2.44M – 285
2024
Q4 		$2.44M Sell
91,333
-33,851
-27% -$1.08M 0.35% 138
2024
Q3 		$3.34M Buy
+125,184
New +$2.49M 0.5% 105
2022
Q4 		– Sell
-122,804
Closed -$1.21M – 289
2022
Q3 		$1.21M Buy
+122,804
New +$1.24M 0.26% 165

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EAM Investors's EWTX Position: Q1 2025 in Review

EAM Investors sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 91,333 shares — an estimated $2.44M sold.

EAM Investors first reported a position in EWTX in Q3 2022 and held it in 3 quarters. The position peaked at $3.34M in Q3 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • EAM Investors reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EAM Investors sold 91,333 Edgewise Therapeutics shares in Q1 2025, an estimated $2.44M.
  • EAM Investors first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 3 quarters.
  • EAM Investors's Edgewise Therapeutics position peaked at $3.34M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on EAM Investors's 13F filing for Q1 2025, filed 13 May 2025.